Vetr Inc. announced Celgene Corporation (NASDAQ:CELG), bumping up its stock price target to $125.81 today
- Updated: November 27, 2016
Just yesterday Celgene Corporation (NASDAQ:CELG) traded 0.17% higher at $121.06. CELG’s 50-day average is $108.41 and its two hundred day average is $106.51. With the last close up 13.66% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 4,493,930
In a report released on 11/28/2016 Vetr Inc. increased the stock price target of Celgene Corporation (NASDAQ:CELG) to $125.81 reporting a possible upside of 0.04%.
Previously on Monday November 21, 2016, Vetr Inc. reported on Celgene Corporation (NASDAQ:CELG) increased the target price from $0.00 to $129.47. At the time, this indicated a possible upside of 0.04%.
See Chart Below
Celgene Corporation has a 52 week low of $93.05 and a 52 week high of $127.00 with a P/E ratio of 45.98 CELG’s total market value is presently $0.
A total of 22 equity analysts have released a ratings update on CELG. Ten equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, four equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $136.82.
Brief Synopsis About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.